Genentech changes ranibizumab programs
Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.
South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis)-including Lucentis Access Solutions and the Genentech Access to Care Foundation-in an effort to improve enrollment timing and broaden eligibility requirements.
The changes include:
For more information, physicians and patients may contact 866/724-9394 or http://www.lucentisaccesssolutions.com/.
Recent Videos
Related Content
